Search
Weiming Pharmaceutical: Tianjin Subsidiary Halts Production and Sales
2025-04-24 /
Read about 0 minute
Author：小编
On April 22, Tianjin Weiming, a key holding subsidiary of Weiming Pharmaceutical, saw its operations temporarily halted by the Tianjin Drug Administration due to issues related to production and sales. Tianjin Weiming's flagship product, human interferon, generated RMB 217 million in revenue in 2024, comprising 60% of the parent company's total earnings. Despite this significant contribution, the subsidiary incurred a net loss of RMB 14.0037 million, adversely affecting Weiming Pharmaceutical's overall production and operations. Should production not resume within three months, Weiming Pharmaceutical may face additional risk warnings.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
